Creative Planning Acquires Shares of 17,000 T2 Biosystems Inc (NASDAQ:TTOO)

Share on StockTwits

Creative Planning acquired a new stake in shares of T2 Biosystems Inc (NASDAQ:TTOO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,000 shares of the medical equipment provider’s stock, valued at approximately $43,000.

A number of other hedge funds also recently modified their holdings of TTOO. Private Advisor Group LLC purchased a new stake in T2 Biosystems during the second quarter valued at approximately $27,000. Macquarie Group Ltd. purchased a new stake in T2 Biosystems during the second quarter valued at approximately $27,000. Commonwealth Equity Services LLC purchased a new stake in T2 Biosystems during the third quarter valued at approximately $32,000. Tower Research Capital LLC TRC raised its position in T2 Biosystems by 1,217.6% during the second quarter. Tower Research Capital LLC TRC now owns 22,399 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 20,699 shares during the period. Finally, Wiley BROS. Aintree Capital LLC raised its position in T2 Biosystems by 150.0% during the second quarter. Wiley BROS. Aintree Capital LLC now owns 25,000 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 15,000 shares during the period. Institutional investors and hedge funds own 37.75% of the company’s stock.

Shares of NASDAQ TTOO opened at $1.75 on Tuesday. The business’s 50 day moving average price is $2.43 and its 200-day moving average price is $1.95. T2 Biosystems Inc has a fifty-two week low of $0.52 and a fifty-two week high of $5.38. The company has a market cap of $67.25 million, a price-to-earnings ratio of -1.39 and a beta of 1.23.

Several equities research analysts have recently weighed in on TTOO shares. HC Wainwright reiterated a “hold” rating on shares of T2 Biosystems in a report on Wednesday, August 7th. Leerink Swann set a $5.00 price target on T2 Biosystems and gave the stock a “buy” rating in a report on Thursday, September 12th. Svb Leerink increased their price target on T2 Biosystems from $3.00 to $5.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Alliance Global Partners downgraded T2 Biosystems from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $5.00 to $0.40 in a report on Thursday, August 1st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $3.00 price target on shares of T2 Biosystems in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. T2 Biosystems has a consensus rating of “Hold” and an average price target of $5.13.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.

Featured Story: What is the outlook for the FAANG stocks?

Want to see what other hedge funds are holding TTOO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for T2 Biosystems Inc (NASDAQ:TTOO).

Institutional Ownership by Quarter for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.